Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among…
Articles by Lindsey Shapiro, PhD
Relacorilant lowered the risk of disease progression and death by about 30% when used on top of standard chemotherapy in…
When added to standard care, Imunon’s immunotherapy candidate IMNN-001 extended the average survival for people with newly diagnosed advanced…
The U.S. Food and Drug Administration (FDA) has given Verastem Oncology the green light to start clinical testing of…
Tepylute (thiotepa), a chemotherapy medication from Shorla Oncology that was approved last year for treating certain breast and ovarian…
Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including…
Blood levels of the MUC5AC protein could help predict outcomes in people who have surgery for pancreatic ductal adenocarcinoma (PDA),…
April 21 marks AML World Awareness Day — a global effort to boost recognition of acute myeloid leukemia (AML)…
The LY6H and GRM3 proteins could serve as potential biomarkers of glioma-related epilepsy (GRE), according to a study. Among…
Adding the investigational therapy LAM561 to standard of care treatment may delay disease progression or death in people with newly…